Emily Anne Kiernan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/960070/publications.pdf

Version: 2024-02-01

20 papers 904 citations

759055 12 h-index 18 g-index

20 all docs

20 docs citations

times ranked

20

928 citing authors

#	Article	IF	CITATIONS
1	Elevated methemoglobin levels in patients treated with hydroxocobalamin: a case series and <i>in-vitro</i> analysis. Clinical Toxicology, 2022, , 1-7.	0.8	1
2	A Brief Overview of the National Outbreak of e-Cigarette, or Vaping, Product Use-Associated Lung Injury and the Primary Causes. Chest, 2021, 159, 426-431.	0.4	16
3	Two Cases of Serotonin Syndrome After Bupropion Overdose Treated With Cyproheptadine. Journal of Emergency Medicine, 2021, 60, e67-e71.	0.3	5
4	Articles You Might Have Missed. Journal of Medical Toxicology, 2021, 17, 227-231.	0.8	0
5	Articles You Might Have Missed—AACT Radiation Special Interest Section. Journal of Medical Toxicology, 2021, 17, 312-316.	0.8	0
6	Single-Agent Bupropion Exposures: Clinical Characteristics and an Atypical Cause of Serotonin Toxicity. Journal of Medical Toxicology, 2020, 16, 12-16.	0.8	17
7	Elevated Methemoglobin Levels in a Patient Treated with Hydroxocobalamin After Suspected Cyanide Exposure. Journal of Emergency Medicine, 2020, 59, e157-e162.	0.3	2
8	Pathological findings in suspected cases of e-cigarette, or vaping, product use-associated lung injury (EVALI): a case series. Lancet Respiratory Medicine, the, 2020, 8, 1219-1232.	5.2	30
9	All that glitters is not gold: Mercury poisoning in a family mimicking an infectious illness. Current Problems in Pediatric and Adolescent Health Care, 2020, 50, 100758.	0.8	2
10	Hospitalizations and Deaths Associated with EVALI. New England Journal of Medicine, 2020, 382, 1589-1598.	13.9	139
11	Demographics, Substance Use Behaviors, and Clinical Characteristics of Adolescents With e-Cigarette, or Vaping, Product Use–Associated Lung Injury (EVALI) in the United States in 2019. JAMA Pediatrics, 2020, 174, e200756.	3.3	42
12	Update: Interim Guidance for Health Care Professionals Evaluating and Caring for Patients with Suspected E-cigarette, or Vaping, Product Use–Associated Lung Injury and for Reducing the Risk for Rehospitalization and Death Following Hospital Discharge — United States, December 2019. Morbidity and Mortality Weekly Report, 2020, 68, 1189-1194.	9.0	37
13	Clinical and Demographic Parameters of Patients Treated Using a Sepsis Protocol. Clinical Therapeutics, 2019, 41, 1020-1028.	1.1	3
14	Update: Interim guidance for health care providers evaluating and caring for patients with suspected e-cigarette, or vaping, product use associated lung Injury $\hat{a} \in \mathbb{C}$ United States, October 2019. American Journal of Transplantation, 2019, 19, 3420-3428.	2.6	19
15	Severe Pulmonary Disease Associated with Electronic-Cigarette–Product Use — Interim Guidance. Morbidity and Mortality Weekly Report, 2019, 68, 787-790.	9.0	179
16	Update: Interim Guidance for Health Care Providers Evaluating and Caring for Patients with Suspected E-cigarette, or Vaping, Product Use Associated Lung Injury â€" United States, October 2019. Morbidity and Mortality Weekly Report, 2019, 68, 919-927.	9.0	192
17	Update: Characteristics of Patients in a National Outbreak of E-cigarette, or Vaping, Product Use–Associated Lung Injuries — United States, October 2019. Morbidity and Mortality Weekly Report, 2019, 68, 985-989.	9.0	92
18	Characteristics of Hospitalized and Nonhospitalized Patients in a Nationwide Outbreak of E-cigarette, or Vaping, Product Use–Associated Lung Injury — United States, November 2019. Morbidity and Mortality Weekly Report, 2019, 68, 1076-1080.	9.0	64

#	Article	IF	CITATIONS
19	Update: Interim Guidance for Health Care Providers for Managing Patients with Suspected E-cigarette, or Vaping, Product Use–Associated Lung Injury — United States, November 2019. Morbidity and Mortality Weekly Report, 2019, 68, 1081-1086.	9.0	61
20	Perception and Practice Among Emergency Medicine Health Care Providers Regarding Discharging Patients After Opioid Administration. Clinical Therapeutics, 2018, 40, 214-223.e5.	1.1	3